Global Anticoagulants Market Report, 2019: Industry Size & Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies (2018-2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Anticoagulants Market Size, Market Share, Application Analysis, Regional
Outlook, Growth Trends, Key Players, Competitive Strategies and
Forecasts, 2018 to 2026” report has been added to ResearchAndMarkets.com’s
offering.

The global anticoagulants market was valued at US$ 33,150.7 Mn in 2017
and is expected to grow at a compound annual growth rate (CAGR) of 6.6%
during the forecast period from 2018 to 2026.

The global anticoagulants market is projected to grow at a steady rate
during the forecast period, attributable to the launch of drugs with
lower side effects and higher efficacy, the growing prevalence of
cardiovascular diseases globally and higher adoption of novel oral
anticoagulants (NOACs) in North America and Europe.

The promising pipeline will further drive the market during the forecast
period. For instance, Ionis Pharmaceutical is developing a novel
antisense drug named IONIS-FXIRx that is designed to reduce the
production of coagulation factor XI that plays a key role in the
proliferation of clots. The drug is in phase II of clinical trials and
claims to have positive results when tested in patients undergoing
replacement to prevent venous thrombosis.

Espero Biopharma phase III candidate, a vitamin K antagonist named
Tecarfarin, claims of having fewer adverse effects and lesser drug-drug
interaction as compared to warfarin. Thus, these promising drug
candidates will drive the market in the latter stage of the forecast
period.

In terms of application, the market is segmented into atrial
fibrillation & heart attacks, strokes, deep vein thrombosis (DVT), and
pulmonary embolism. In 2017, atrial fibrillation (AF) & heart attacks
held the largest share in the anticoagulants market owing to a large
target population of patients suffering from atrial fibrillation and
growing incidence of heart attacks. According to a recent study in
Britain, it is estimated that 1.4 million British people are at high
risk of strokes due to non-valvular atrial fibrillation (NVAF).

AF prevalence is higher in North America and Asia Pacific, thereby
driving the market due to increased usage of anticoagulants. Deep vein
thrombosis is expected to show significant growth rate during the
forecast period, due to growing cases and products specifically
targeting DVT.

In terms of geography, North America held the largest share of over 48%
in the global anticoagulants market. The increasing usage of NOACs in
the region is the major driving factor for the growth of the market.
Xarelto and Eliquis are the most prescribed drugs in the U.S. followed
by warfarin. Structured approval policies by the U.S. Food and Drug
Administration (FDA) and efficient reimbursement scenario drive the
market in North America.

Asia Pacific emerged as the fastest growing region owing to the high
target population, lucrative opportunities for foreign players to invest
in an ever-growing prevalence of cardiovascular diseases. Furthermore, a
growing number of pharmaceutical players indulging in research &
development of anticoagulants and growing health awareness will further
drive the market.

The key players currently engaged in anticoagulants market include Bayer
AG, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH,
Bristol-Myers Squibb Company, Pfizer, Inc., Daiichi Sankyo Company
Limited, and Portola Pharmaceuticals, Inc. among others.

Key Market Movements

• Promising pipeline for anticoagulants in North America and Europe to
  drive the market during the forecast period
• Growing research and development by pharmaceutical players further
  boost market growth
• The rising prevalence of a cardiovascular diseases such as atrial
  fibrillation, DVT and coronary heart diseases

Topics Covered

Chapter 1. Preface

1.1. Report Description

1.2. Research Scope

1.3. Research Methodology

1.4. Market Segmentation

Chapter 2. Executive Summary

2.1. Global Anticoagulants Market Portraiture

2.2. Global Anticoagulants Market, by Drug Class, 2017 (US$ Mn)

2.3. Global Anticoagulants Market, by Application, 2017 (US$ Mn)

2.4. Global Anticoagulants Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulants: Market Dynamics and Outlook

3.1. Market Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography, 2017

3.6. Competitive Analysis: Global Anticoagulants Market, by Key Players,
2017

Chapter 4. Global Anticoagulants Market, by Drug Class,
2016-2026 (US$ Mn)

4.1. Overview

4.2. Novel Oral Anticoagulants (NOACs)

4.3. Vitamin K Antagonists

4.4. Heparins & Low Molecular Weight Heparins (LMWH)

4.5. Antiplatelet Agents

4.6. Thrombolytic Agents

4.7. Direct Thrombin Inhibitors

4.8. Pipeline Analysis (Forecast for Phase III drugs till 2026)

Chapter 5. Global Anticoagulants Market, by Application Type,
2016-2026 (US$ Mn)

5.1. Overview

5.2. Atrial Fibrillation & Heart Attacks

5.3. Strokes

5.4. Deep Vein Thrombosis (DVT)

5.5. Pulmonary Embolism

Chapter 6. Global Anticoagulants Market, by Geography, 2016 –
2026 (US$ Mn)

6.1. North America Anticoagulants Market Analysis, 2016 – 2026

6.2. Europe Anticoagulants Market Analysis, 2016 – 2026

6.3. Asia Pacific Anticoagulants Market Analysis, 2016 – 2026

6.4. Latin America Anticoagulants Market Analysis, 2016 – 2026

6.5. Middle East & Africa Anticoagulants Market, 2016 – 2026

Chapter 7. Company Profiles

7.1. Boehringer Ingelheim Internation GmbH

7.1.1. Business Description

7.1.2. Financial Information (Subject to Data Availability)

7.1.3. Product Portfolio

7.1.4. News Coverage

7.2. Bayer AG

7.3. Johnson & Johnson Inc.

7.4. Bristol-Myers Squibb Company

7.5. Pfizer Inc.

7.6. Daiichi-Sankyo Company Limited

7.7. Portola Pharmaceuticals Inc.

7.8. Sanofi S.A.

7.9. Aspen Holdings

7.10. GlaxoSmithKline PLC

For more information about this report visit https://www.researchandmarkets.com/research/br3x74/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs